| ||
| Peregrine Provides Update on Government-Sponsored Research Program MarketWatch (press release) Bavituximab is currently in two Phase IIb clinical trials for non-small cell lung cancer (NSCLC), three Phase II clinical trials in NSCLC and advanced ... See all stories on this topic » | ||
| : Multiple Insiders of Synta Pharmaceuticals Corp.(NasdaqGM: SNTA) bought ... Trading Markets (press release) Its research and development programs include STA-9090, an Hsp90 inhibitor that is in Phase II stage for non-small cell lung cancer and gastrointestinal ... See all stories on this topic » |
Tip: Use site restrict in your query to search within a site (site:nytimes.com or site:.edu). Learn more.
Remove this alert.
Create another alert.
Manage your alerts.
The inhalation of tobacco smoke by nonsmokers who share living or working quarters with smokers, also is an established risk factor for the development of lung cancer.
ReplyDeleteLung cancer treatment